BACKGROUND: It is commonly believed that, before being diagnosed after onset of symptoms, diffuse low-grade glioma evolve silently for a long time. The present study aimed to estimate for the first time the exact duration of this silent phase, during which the glioma is radiologically visible but undiscovered. METHODS: We retrospectively reviewed our French national database of diffuse low-grade glioma, searching for patients with an MRI-based assessment of their velocity of diameter growth at diagnosis and before any treatment (at least three MRIs over more than 6 months). For each patient, the duration of the silent phase was estimated by the formula: duration = initial diameter / initial velocity of growth. RESULTS: A total of 148 patients were included in the study. The mean lead-time duration (i.e., duration of the silent phase) was 14.0 ± 7.8 years (median, 11.6 ; range, 1.6-39.4). The lead-time is statistically not correlated to the tumor volume. It is markedly decreasing with the velocity of diameter expansion. CONCLUSIONS: Diffuse low-grade glioma are radiologically detectable but clinically silent for more than a decade. Such a long period of silent evolution could explain our current failure to cure these tumors. It can also be viewed as a window of opportunity to detect these tumors earlier, suggesting the need to set up a screening program.
BACKGROUND: It is commonly believed that, before being diagnosed after onset of symptoms, diffuse low-grade glioma evolve silently for a long time. The present study aimed to estimate for the first time the exact duration of this silent phase, during which the glioma is radiologically visible but undiscovered. METHODS: We retrospectively reviewed our French national database of diffuse low-grade glioma, searching for patients with an MRI-based assessment of their velocity of diameter growth at diagnosis and before any treatment (at least three MRIs over more than 6 months). For each patient, the duration of the silent phase was estimated by the formula: duration = initial diameter / initial velocity of growth. RESULTS: A total of 148 patients were included in the study. The mean lead-time duration (i.e., duration of the silent phase) was 14.0 ± 7.8 years (median, 11.6 ; range, 1.6-39.4). The lead-time is statistically not correlated to the tumor volume. It is markedly decreasing with the velocity of diameter expansion. CONCLUSIONS: Diffuse low-grade glioma are radiologically detectable but clinically silent for more than a decade. Such a long period of silent evolution could explain our current failure to cure these tumors. It can also be viewed as a window of opportunity to detect these tumors earlier, suggesting the need to set up a screening program.
Authors: Hans Kristian Bø; Ole Solheim; Asgeir Store Jakola; Kjell-Arne Kvistad; Ingerid Reinertsen; Erik Magnus Berntsen Journal: J Neurooncol Date: 2016-11-11 Impact factor: 4.130
Authors: Alba Corell; Tomás Gómez Vecchio; Sandra Ferreyra Vega; Anna Dénes; Alice Neimantaite; Alexander Hagerius; Hanna Barchéus; Ole Solheim; Cecilia Lindskog; Thomas Olsson Bontell; Helena Carén; Asgeir S Jakola; Anja Smits Journal: Neurooncol Adv Date: 2022-06-04
Authors: Hiroyuki Tatekawa; Hiroyuki Uetani; Akifumi Hagiwara; Jingwen Yao; Talia C Oughourlian; Issei Ueda; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Shadfar Bahri; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson Journal: J Neurooncol Date: 2021-03-11 Impact factor: 4.130
Authors: Mohammed Jaber; Christian Ewelt; Johannes Wölfer; Benjamin Brokinkel; Christian Thomas; Martin Hasselblatt; Oliver Grauer; Walter Stummer Journal: Neurosurgery Date: 2019-06-01 Impact factor: 4.654